Because irritable bowel syndrome (IBS) is a functional medical condition for which there is no curative therapy, treatment goals emphasize relieving gastrointestinal (GI) symptoms and optimizing the quality of life (QOL). This study sought to characterize the magnitude of the associations between QOL impairment, fear of IBS symptoms, and confounding variables.
INTRODUCTION
Irritable bowel syndrome (IBS) is a common, oft en disabling, gastrointestinal (GI) disorder characterized by abdominal pain associated with altered bowel habits (i.e., constipation and/or diarrhea) ( 1 ) . As one of the most common diagnoses seen by gastroenterologists and primary care physicians ( 2 ) , IBS exacts substantial economic ( 3 ) and social ( 4, 5 ) costs. Its impact on health-related quality of life (QOL) rivals that of diabetes and end-stage renal disease ( 6 ) .
Because IBS lacks a reliable biomarker, it is best understood from a biopsychosocial model ( 7 ) that emphasizes the reciprocal and interactive relationship among biological and psychosocial factors. With respect to psychosocial factors, the way patients' process information-expressed through their beliefs, expectations, thinking style, and other cognitive variables-has a particularly strong impact on IBS outcomes. One cognitive variable that has received a great deal of attention is GI-specifi c anxiety (GSA ( 8 ) ). GSA refers to a specifi c fear of GI symptoms (e.g., abdominal pain or discomfort). A person with high GSA is likely to become acutely fearful because of beliefs that GI symptoms have aversive physical, psychological, or social consequences. Th e belief that GI symptoms are signs of imminent threat is thought to increase the frequency or intensity of symptoms, heighten central nervous system hypervigilance toward potentially aversive visceral stimuli or their cues, and cause excessive avoidance of activities or situations where GI symptoms are expected to occur. GSA diff ers from other clinically relevant psychological variables such as general anxiety, which is "free-fl oating" and not linked to a specifi c cause or situation, or general distress.
Support for the importance of the GSA construct comes from research showing that fear of GI symptoms mediates the relationship between general distress and GI symptom severity and is a key predictor of IBS diagnosis ( 9 ) . Regarded as a marker of overresponsiveness to visceral sensations, fear of GI symptoms is believed to aggravate symptoms through alterations in autonomic and pain facilitation, as well as cognitive mechanisms ( 9 ) . Heightened fear of GI symptoms may also aggravate IBS-specifi c dimensions of the QOL, which is increasingly recognized as a critical health outcome, particularly for benign medical illnesses like IBS whose impact (and treatment response) is gauged by its dayto-day burden ( 10, 11 ) . Th e extent to which patients' fears impact the specifi c dimensions of the QOL relevant to IBS patients (i.e., IBS-specifi c QOL) has not been explored. A meaningful relationship between IBS-QOL and GI symptom fear would require evidence that it is independent of the eff ects of confounding factors such as GI symptom severity, emotional distress, demographics, and personality style (e.g., neuroticism) that bear on QOL. To this end, we predicted the following: (i) fear of GI symptoms will be signifi cantly associated with poorer IBS-specifi c QOL; (ii) the relationship between fear of GI symptoms and QOL will remain even aft er controlling for potentially confounding variables; and (iii) the magnitude of the relationship between QOL and fear of GI symptoms will be strongest for measures of QOL owing to IBS symptoms than for generic measures of QOL, which have been the primary focus of IBS researchers.
METHODS
Participants included 234 consecutively evaluated IBS patients recruited at two tertiary academic medical centers in Buff alo, NY and Chicago, IL, as part of an National Institutes of Health-funded clinical trial, the details of which can be found elsewhere ( 12 ) . Participants were enrolled primarily through local media coverage, community advertising, and physician referral. To be eligible for the study, all participants must have met the Rome III diagnostic criteria ( 13 ) as determined by a board-certifi ed gastroenterologist. Because this study was conducted as part of a clinical trial for moderate to severely aff ected patients with IBS ( 12 ) participants must have also reported IBS symptoms of at least moderate intensity (i.e., symptom frequency of at least twice weekly for a minimum duration of 6 months and causing life interference). Subjects with presence of a comorbid organic GI illness that would adequately explain GI symptoms, mental retardation, current or past diagnosis of schizophrenia or other psychotic disorders, current diagnosis of depression with suicidal ideation, and current diagnosis of psychoactive substance abuse were excluded. Institutional review board approval (University at Buff alo, 19 May 2009; Northwestern University, 19 December 2008) and written, signed, informed consent were obtained before study initiation. Th e study was completed in full compliance with the Declaration of Helsinki.
Procedure
Aft er a brief telephonic interview to determine eligibility, participants were scheduled for a medical examination administered by a board-certifi ed gastroenterologist to confi rm Rome diagnosis of IBS and testing drawn from a battery of psychometrically validated measures detailed below.
Measures
Fear of GI symptoms . Fear of GI symptoms was assessed using the validated (VSI ( 8 ) ) 15-item Visceral Sensitivity Index. Items were rated on a 6-point Likert scale (0=strongly disagree to 5=strongly agree) and specify a possible negative consequence to the experience of GI symptom-specifi c anxiety. Items were reverse scored and summed, yielding a range of scores from 0 (no fear of GI symptoms) to 75 (strong fear of GI symptoms).
IBS symptom severity . Global IBS symptom severity was measured using the single item UCLA Global Severity of GI Symptoms Scale. Th e UCLA Global Severity of GI Symptoms Scale is a validated ( 14 ) 21-Point rating scale that requires participants to rate the overall severity of their GI symptoms from 0 (no symptoms) to 20 (most intense symptoms imaginable) during the past week. ( 15 ) is a 34-item measure constructed specifi cally to assess the perceived impact of IBS on the QOL in eight domains (dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual dysfunction, and relationships). Each item was scored on a fi ve-point scale (1=not at all to 5=a great deal). Items were scored to derive an overall total score of IBS-related QOL ranging from 0 (poor QOL) to 100 (maximum QOL).
IBS-specifi c QOL . Th e IBS-QOL
Global QOL . Th e 12-item Short Form or SF-12 ( 16 ) is a generic QOL measure based on the SF-36. Th e SF-12 captures approximately 90% of the variance of the SF-36 ( 17 ) . Th e SF-12 provides two summary indices of health-related quality of life: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). PCS and MCS scores were computed using the scores of 12 questions and range from 0 to 100 (100 (M=50, s.d.=10), where zero indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
Neuroticism . We used the short form version of the Trait subscale of the State-Trait Anxiety Inventory (STAI Trait) to measure the trait of neuroticism. Its 20 items require subjects ( 18 ) to indicate how they generally feel by rating the frequency of their feelings of anxiety on a four-point scale ranging from 1 (almost never) to 4 (almost always). High scores are characteristic of patients with a general disposition toward stress responsiveness.
Global distress . Psychological distress was assessed using the 18-item version of the Brief Symptom Inventory ( 19 ) . Th e BSI-18
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Fear of IBS Symptoms and Quality of Life on a 21-point scale, which is consistent with other studies ( 14 ) . Patients with a mean of 56.5 (s.d.=18.9) on the IBS-QOL are regarded as having signifi cant QOL impairment caused by IBS symptoms ( 24 ) . Sample means for the physical component (SF-12 PCS; M =43.8, s.d.=9.4) and the mental component (SF-12 MCS; M =40.9, s.d.=10.7) of the global QOL measure fall within "impaired" ranges of mental and physical functioning for IBS patients ( 25 ) . With respect to distress variables, the mean trait anxiety score (20.5, s.d.=6.2) fell at the 75th percentile, meaning that patients scored, on average, higher than the 75th percentile of other individuals completing the short form of the STAI-Trait ( 26 ) . A raw score of 14.3 (s.d.=12.1) on the measure of global psychological distress (BSI-GSI) corresponds with a percentile rank of 56 ( 19 ) . Table 2 depicts the means and 95% confi dence intervals of the study variables for each level of the categorical, independent variables. Participants with less than high school education had lower requires respondents to indicate on a fi ve-point scale (0=not at all to 4=extremely) their level of distress of 18 somatic and psychological symptoms for three types of problems (e.g., anxiety, somatization, and depression). Th e average intensity of all items yields a composite index of psychological distress (the Global Severity Index (GSI)). Th e GSI has been used extensively to measure psychological distress in patients with IBS ( 20, 21 ) .
Bivariate analyses

Statistical analysis
Descriptive statistics (e.g., means, s.d., and percentages) were used to summarize demographic and clinical data. Bivariate analyses were used to examine the relationships among the variables before multivariate modeling. Means and 95% confi dence intervals were computed for the study (i.e., dependent) variables within the independent, categorical variables (i.e., gender, education, marital status, and IBS subtype). Pearson's correlation coeffi cients were generated to characterize the association between independent, continuous variables, and the study variables. Alpha levels for determining statistical signifi cance were set at 0.01 to correct for multiple analyses. For the confi rmatory multivariate analyses, the independent variables were grouped into three conceptually distinct categories. Th e fi rst category consisted of sociodemographics-age, sex, education, yearly income, and marital status (married vs. other). Th e second category consisted of clinical features-duration of symptoms, IBS subtype, IBS severity over the past 7 days, and psychological dysfunction (trait anxiety and global psychological distress). Th e third category consisted of fear of GI symptoms. Using hierarchical linear regression analyses, each category of predictors was entered in the following order for each dependent variable: sociodemographics (Step 1), clinical features (Step 2), and fear of GI symptoms (Step 3). Dependent variables consisted of IBS-QOL and two indices of generic QOL: the PCS score of the SF-12 (SF-12 PCS) and its MCS score (SF-12 MCS). We used SPSS version 22 (Chicago, IL) to perform all statistical analyses.
Although this is a secondary analysis of a larger data set of an National Institutes of Health study, the minimum number of subjects for this substudy was determined by an a p riori power analysis. On the basis of a probability level of 0.05, 11 predictors, an anticipated eff ect size of 0.15, and power level of 0.9, the minimum number of subjects was 152 ( 22, 23 ) . To increase rigor (i.e., reducing probability of making a Type 1 error), we conducted a retrospective power analysis using an alpha level of 0.01, which yielded a minimum sample size of 198. With a sample size of 234, it is unlikely that fi ndings described below can be attributed to a limited sample size.
RESULTS
Descriptive analyses
Demographic and clinical characteristics of the sample IBS are presented in Table 1 . Th e mean total score on the UCLA Global Severity of GI Symptoms Scale for the sample was 11.1 (s.d.=3.9), which corresponds to a moderate level of GI symptom severity Lackner et al.
scores on the SF-12 PCS compared with all other participants. Similar scores were observed for the subcategories of gender, marital status, and IBS subtype on all of the three QOL outcome measures. Generally speaking, clinical and potentially confounding variables and fear of GI symptoms were, as predicted, interrelated in the expected directions. Fear of GI symptoms was signifi cantly and positively associated with both measures of psychological dysfunction (i.e. global distress and neuroticism). Individuals with stronger fears of GI symptoms reported higher levels of distress as measured by the BSI-GSI. Th ey also reported higher levels of trait anxiety (neuroticism) as measured by the Trait Scale of the STAI. Th at is, individuals with stronger fears of GI symptoms reported a general disposition to respond fearfully to stressful situations. Fear of GI symptoms was signifi cantly associated with global severity of IBS symptoms but not with duration of symptoms. With respect to QOL, fear of GI symptoms was correlated with both generic and disease-specifi c indices of QOL. With respect to these correlations, the strongest one was with the IBS-QOL, with patients with stronger fears of GI symptoms reporting greater QOL impairment due to IBS. Intercorrelations among all of the independent and dependent continuous variables are available as a Supplementary Table online.
Regression analyses
For each of the fi nal models, data were screened for violations of the assumptions of linear regression prior to analysis. Boxplots and stem-and-leaf plots of the unstandarized residuals of each of the dependent variables suggest that the residuals are normally distributed. Also, Shapiro-Wilk statistics were all above 0.92 and nonsignifi cant. Scatterplots of the independent and dependent variables indicate linear relationships with no observed outliers. Durbin-Watson statistics were all between 1.4 and 2.6, which suggest independent errors. Examination of scatterplots of residuals vs predicted values indicates that the variances of the residuals are consistent over a range of predicted values and provide evidence of homogeneity of variance. Finally, multicollinearity does not appear to be an issue, with all variance infl ation factors below 4.01 and tolerance factors above 0.29. Table 3 shows the results of the sequential multiple linear regression analyses for the SF-12 PCS, SF-12 MCS, and IBS-QOL. In the fi rst regression with the SF-12 PCS as the dependent variable, sociodemographic variables accounted for 13.7% of the variance. Yearly income was the only statistically signifi cant independent predictor. In step 2, clinical variables explained an additional 14.0% of unique variance in the SF-12 PCS, with global severity of IBS symptoms and global psychological distress emerging as independent signifi cant predictors. In the third and fi nal step, fear of GI symptoms accounted for an additional 3.5% of the variance ( P <0.01). To understand the nature of the relationship between fear of IBS symptoms and QOL impairment due to IBS, we relied on standardized coeffi cients, which are also called "beta weights" and designated by the Greek letter β ( Table 3 ). Th ey serve as standardized eff ect size statistics that are expressed in standard deviation units. It is diffi cult to compare the coeffi cient for diff erent variables directly because they are typically measured on diff erent scales. By converting numerical values to a common, standardized regression coeffi cient, we can directly compare the relationships between variables in the equation regardless of their unit of measurement (e.g., education levels, income, age, and pain intensity). Standardized regression coeffi cients measure change in the dependent variable that is produced by a 1 s.d. change in the predictor variable. In the fi rst regression equation, a 1 s.d. change in fear of GI symptoms equals −0.22 s.d. in the SF-12 PCS in the direction of worse physical QOL.
In the second regression with the SF-12 MCS as the dependent variable, sociodemographics accounted for only 4.3% of the variance. None of these factors in step 1 was a signifi cant independent predictor. In step 2, the addition of clinical variables in the model predicted 39.8% of unique variance. Neuroticism and global psychological distress emerged as signifi cant independent predictors of mental QOL. Finally, in step 3, fear of GI symptoms did not add 
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tion being the only signifi cant independent predictor. In step 2, clinical variables explained an additional 24.4% of the variance in IBS-QOL, with IBS symptom severity, trait anxiety, and global psychological distress emerging as signifi cant predictors. Finally, the addition of fear of GI symptoms in step 3 accounted any predictive value to the model. In the fi nal model, clinical variables (i.e., neuroticism and global distress) were the best predictors of the mental aspect of QOL.
In the fi nal regression analysis, sociodemographics (step 1) accounted for 9.9% of the variance in IBS-QOL, with educa- 
DISCUSSION
Th is study sought to assess the relationship between QOL and the fears that IBS patients have about their IBS symptoms aft er taking into consideration potentially relevant clinical variables and patient characteristics. We found that a variety of physical (e.g., IBS symptom severity) and psychological (e.g., fear of IBS symptoms) variables were signifi cantly associated with two (SF-12 PCS, IBS-QOL) of the three indices of QOL. Th e strongest relationships were with IBS-QOL. Fear of GI symptoms was the most robust predictor, uniquely explaining 14% of the variance in IBS diseasespecifi c QOL. Patients with the strongest fears about GI symptoms experienced worse QOL as measured by the IBS-QOL. Th e relationship between fear of GI symptoms and IBS-QOL could not be explained by the severity of IBS symptoms, a neurotic personality, sociodemographic variables, or mental distress. Th ese data argue against the notion that the oft en severe loss of quality of life reported by IBS patients is simply due to their mental state or the severity of their IBS symptoms. Th e impact of IBS on QOL hinges to a large extent on the fear patients have about their GI symptoms and their diffi culty working around these fears. To our knowledge, this study is the fi rst linking fear of GI symptoms to IBS-QOL. Understanding the predictors of QOL is critical to clinicians' ability to assess accurately, understand, and respond effi ciently and eff ectively to changes in their patients' QOL ( 27 ) . Current guidelines suggest routine ( 28 ) assessment of QOL in all patients and recommend initiating treatment when QOL is found to be diminished. Because of the global focus of generic measures of QOL, even clinicians who comply with screening recommendations using these tools are hard pressed to determine whether the nature of QOL impairment or their fl uctuations are owing to the problem for which IBS patients seek treatment or coexisting medical problems common to IBS. Previous research ( 21 ) shows that medical conditions highly comorbid with IBS and not with IBS per se are signifi cant drivers of health-related QOL impairment at least as measured by global QOL measures. An advantage of disease-specifi c QOL measures like the IBS-QOL is that they gauge loss of QOL due to IBS. Th e way individuals experience a chronic illness like IBS encompasses many diff erent areas and is infl uenced by numerous factors, including the severity of IBS symptoms as well as their impact on activities of daily living, emotional unpleasantness, and meaning such as the unpredictability and uncontrollability of symptoms ( 29 ) . In our subjects, patients' fear of symptoms was a stronger predictor of IBS QOL impairment than confounding variables including IBS symptom severity. Although somewhat counterintuitive, our data echo the broader health research that has found that fear of pain is more disabling than pain itself in low back pain patients ( 30 ) .
In general, the current study expands the fi ndings of previous research conducted by Jerndal et al. ( 31 ) that has linked fear of GI symptoms as measured with the VSI to generic QOL impairment. Like Jerndal et al. ( 31 ) , we found that patients who report stronger fears of GI symptoms describe worse quality of life. Th ere are, however, important diff erences between our data and theirs. Th ey found that fear of GI symptoms, together with mental well-being and demographic factors (e.g., age), accounted for a statistically signifi cant but small (7%) proportion of the variance in the mental QOL scale of the SF-36. In contrast, our results indicate that, aft er holding psychological distress variables constant, fear of GI symptoms did not contribute a signifi cant amount of unique variance to mental quality of life. In other words, the relationship between fear of GI symptoms and the mental well-being aspect of generic quality of life is largely dependent on broad-based psychological factors including personality style (neuroticism), demographics, and the overall level of psychological distress. In addition, we found that fear of GI symptoms accounted for a signifi cant proportion of the variance in physical well-being, which Jerndal et al. ( 31 ) found unrelated to the fear of GI symptoms. We are hard pressed to provide a defi nitive explanation of the diff erent patterns of data. One possibility is that our statistical approach was able to tease out the shared variance due to fear of GI symptoms, demographic variables, and global distress. Jerndal et al. ( 31 ) did not systematically assess incremental variance due to each variable. Th is explanation does not, however, explain our fi nding that fear of GI symptoms is associated with generic physical QOL. Th e disparity cannot be explained by diff erences in sample demographics, although they were sampled in diff erent countries (USA, Sweden). Subjects in both studies were similar across multiple demographic dimensions (e.g., age, bowel type, gender 
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therapeutic objectives at the cost of their relationship with their physician and the effi ciency of care they receive. We recognize that there are several limitations inherent in this study. Because our data are cross-sectional, we do not intend to suggest that the fi ndings demonstrate causal relationships between fear of GI symptoms and quality of life. At best, our data can be construed as suggestive of a possible causal relationship between GI symptom fears and QOL that could be confi rmed through longitudinal analyses. Although our measures satisfy accepted standards for psychometric soundness, data are based on a self-report, which means they are subject to some bias and measurement error. By relying on a single item measure of GI symptom severity ( 14 ) , our fi ndings are vulnerable to a greater measurement error and reduced reliability than had we used a multi-item measure (e.g., the IBS Symptom Severity Scale). We were concerned that, for the purpose of this study, the IBS Symptom Severity Scale would have introduced its own measurement error because it conceptualizes symptom severity in terms of patient satisfaction, which is regarded by some researchers as a defi ning aspect of QOL ( 36 ) . A reasonable concern is whether the magnitude of the observed fi ndings is due to measurement overlap of items of the VSI and QOL that assess the same underlying concept (e.g., negative emotion). Recognizing this possibility, we statistically controlled for the possible confounding eff ect of potential confounds (e.g., distress, symptom severity, and so on) to determine the amount of variance in QOL due to VSI above and beyond that explained by control variables. Even when these factors were controlled, fear of GI symptoms explained a signifi cant amount of variance in the IBS-QOL and to a lesser extent the physical aspect of QOL. Th e strength of the bivariate correlation between VSI and the mental aspect of QOL ( Supplementary Table ) fell below signifi cant levels when demographic and clinical variables were controlled in regression analyses. It is possible that a third, unexplored variable accentuates a relationship between VSI and IBS-QOL, in which case our results should be interpreted cautiously. Confi dence in study fi ndings would be strengthened had we included behavioral measures of functional impairment and not relied solely on patients' perceptions of their functional limitations. Because IBS patients have a tendency to appraise situations in a negative light, it is unclear to what extent the reported functional limitations that defi ne QOL refl ect "true" impairment or a test taking style that predisposes them to endorse a wide range of personal problems (negative response bias). Because of the relative demographic homogeneity of our selected sample of patients (mostly white, female, chronically ill, and educated patients seeking nondrug treatment), our results may not generalize to a broader, more diverse population. To increase the generalizability of our fi ndings, it will be important for follow-up studies to draw from populations other than those used in the present study.
Together, this study adds to the literature that patients' fear of GI symptoms, as measured by the VSI, has an important role in the experience of IBS and its impact on the day-to-day lives of its sufferers. Fear of GI symptoms impacts IBS-QOL above and beyond IBS symptom severity and broader emotional, sociodemographic, that the great majority of their patients reported meal-induced symptoms in which case their impact on quality of life may be more strongly governed by peripheral (e.g., exaggerated motor or sensory component of the gastrolic refl ex) vs. central factors. It is believed that more severe IBS symptoms are subject to strong central infl uences compared with less severe symptoms ( 32 ) . Consistent with this view is the fact that our patients had stronger GI symptom fears than those in the study by Jerndal et al. ( 31 ) (mean VSI=34 vs. 44) but comparable levels of mental and physical health-related quality of life.
Our fi ndings have implications for the clinical gastroenterologist whose treatment goals for functional GI disorder patients oft en focus on maximizing the quality of life in the presence of continuing symptoms. Although relief from IBS symptoms is always a primary target for medical intervention, for many IBS patients complete or most complete resolution of symptoms is not possible. Th erefore, the search for dietary or pharmacological treatments to signifi cantly improve the QOL by reducing symptom severity can be a fruitless exercise because, as our study shows, IBS symptom severity and quality of life are to an important extent conceptually and empirically distinct. Further, the impact of GI symptom fears on QOL may actually exceed that of symptoms at least among more severely aff ected IBS patients seen in specialty care clinics ( 32, 33 ) . If a major goal of treatment is to improve patients' QOL, then optimizing treatment gains may involve the integration of symptom self-management treatments (i.e. cognitive behavioral techniques) that tackle the psychological drivers of reduced QOL. Examples of empirically validated selfmanagement treatment include cognitive techniques ( 34 ) that teach patients information processing skills to reduce the eff ect of biased or maladaptive thinking patterns and behavioral ( 35 ) strategies to identify patterns of excessive avoidance that interfere with function and give him/her an opportunity to practice more adaptive ways of behaving that will enhance the health related quality of life.
Our fi ndings also have clinical value for the many gastroenterologists for whom cognitive behavioral techniques is not widely available. For example, the notion that IBS patients' QOL is infl uenced by a host of factors beyond the severity of GI symptoms can prompt gastroenterologists to develop a broader picture of the complexity of their patients' problems, the factors that impact them, and the constraints of therapies at their disposal. Th is information can help physician and patients proactively establish realistic and achievable treatment goals without assuming that the route to improved QOL necessarily depends on relief from GI symptoms. For many patients, symptom relief will improve the QOL. However, patients with strong fears of GI symptoms may experience residual QOL impairment that is beyond the reach of even the most robust medical therapies. Th e typical clinical gastroenterologist may not have the time, expertise, or inclination to fully address patients' illness fears, but the present results at least call attention to the fact that the problems for which patients seek care are not simply a matter of symptom relief-an idea that creates an obligation on the part of the gastroenterologist to achieve an unachievable goal and one that for a signifi cant cohort of more severe patients seen in tertiary care clinics is likely to fall short of clinical, and personality factors. By understanding the unique role that GI symptom fears have on QOL, gastroenterologists can better understand and manage more severe IBS patients seen in specialty care settings.
